Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Short-term Investments (2017 - 2024)

Rein Therapeutics (RNTX) has disclosed Short-term Investments for 9 consecutive years, with $25000.0 as the latest value for Q3 2024.

  • On a quarterly basis, Short-term Investments changed 0.0% to $25000.0 in Q3 2024 year-over-year; TTM through Sep 2024 was $25000.0, a 0.0% change, with the full-year FY2023 number at $25000.0, changed 0.0% from a year prior.
  • Short-term Investments was $25000.0 for Q3 2024 at Rein Therapeutics, roughly flat from $25000.0 in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $48.7 million in Q2 2021 to a low of $25000.0 in Q1 2020.
  • A 5-year average of $8.1 million and a median of $25000.0 in 2020 define the central range for Short-term Investments.
  • Peak YoY movement for Short-term Investments: soared 26936.0% in 2020, then crashed 99.88% in 2023.
  • Rein Therapeutics' Short-term Investments stood at $6.8 million in 2020, then tumbled by 99.63% to $25000.0 in 2021, then changed by 0.0% to $25000.0 in 2022, then changed by 0.0% to $25000.0 in 2023, then changed by 0.0% to $25000.0 in 2024.
  • Per Business Quant, the three most recent readings for RNTX's Short-term Investments are $25000.0 (Q3 2024), $25000.0 (Q2 2024), and $25000.0 (Q1 2024).